Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | METAP2 | P50579 | 3/20 | 0.35 |
| ▸ | METAP1 | P53582 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31065468 | 0.86 | METAP2 (0.42) | ALDH1A1HSD17B10LMNACYP2C19CYP1A2 | |
| SCHEMBL7025313 | 0.85 | CYP2C19 (0.51) | ALDH1A1HSD17B10LMNACYP2C19CYP1A2 | |
| SCHEMBL12934328 | 0.82 | METAP2 (0.40) | ALDH1A1HSD17B10LMNACYP2C19CYP1A2 | |
| SCHEMBL3671186 | 0.82 | METAP2 (0.43) | ALDH1A1HSD17B10LMNACYP2C19CYP1A2 | |
| SCHEMBL12707543 | 0.77 | ALDH1A1 (0.42) | ALDH1A1HSD17B10LMNACYP2C19CYP3A4 | |
| SCHEMBL16626926 | 0.77 | ALDH1A1 (0.42) | ALDH1A1HSD17B10LMNACYP2C19CYP2C9 | |
| SCHEMBL12707546 | 0.77 | ALDH1A1 (0.42) | ALDH1A1HSD17B10LMNACYP2C19CYP3A4 | |
| SCHEMBL818946 | 0.76 | MME (0.41) | ALDH1A1HSD17B10LMNACYP2C19CYP3A4 | |
| SCHEMBL16790758 | 0.75 | APEX1 (0.39) | ALDH1A1CYP1A2CES2 | |
| SCHEMBL7032280 | 0.74 | CYP1A2 (0.49) | ALDH1A1HSD17B10LMNACYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8552062-B2 | Methods for the treatment of metabolic disorders such as diabetes | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-10-08 | — | — | US | disclosed |
| US-7863475-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2011-01-04 | — | — | US | disclosed |
| US-7851494-B2 | Method for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7547802-B2 | 5-[3-(2,6-Dimethylbenzyloxy)-phenyl]-pent-4-enoic acid ethyl ester; insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis, arteriosclerosis; side effects reduction; orally active | WELLSTAT THERAPEUTICS CORPORATION (US) | 2009-06-16 | — | — | US | disclosed |
| US-20080027229-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080021109-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2008-01-24 | — | — | US | disclosed |
| US-20070265322-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070249719-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-10-25 | — | — | US | disclosed |
| US-20070244172-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244171-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070105958-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-05-10 | — | — | US | disclosed |
| US-5006150-A | Herbicides | SANDOZ LTD. (CH) | 1991-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105958-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | GOT2, OAT, CPT1B | ALDH1A1 1035/4885HSD17B10 142/4885LMNA 1879/4885 |
| US-20070244171-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | GOT2, OAT, CPT1B | ALDH1A1 1035/4885HSD17B10 142/4885LMNA 1879/4885 |
| US-20080027229-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | GOT2, OAT, CPT1B | ALDH1A1 1035/4885HSD17B10 142/4885LMNA 1879/4885 |
| US-20070249719-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | GOT2, OAT, CPT1B | ALDH1A1 1035/4885HSD17B10 142/4885LMNA 1879/4885 |
| US-20080021109-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | GOT2, OAT, CPT1B | ALDH1A1 1035/4885HSD17B10 142/4885LMNA 1879/4885 |
| US-20070265322-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | GOT2, OAT, CPT1B | ALDH1A1 1035/4885HSD17B10 142/4885LMNA 1879/4885 |
| US-20070244172-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | GOT2, OAT, CPT1B | ALDH1A1 1035/4885HSD17B10 142/4885LMNA 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.